Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its price objective lowered by Susquehanna Bancshares Inc from $20.00 to $14.00 in a report published on Monday, November 6th, MarketBeat Ratings reports. The brokerage currently has a positive rating on the stock.
A number of other equities analysts have also issued reports on the stock. Credit Suisse Group restated an underperform rating and set a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Royal Bank Of Canada raised their target price on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the stock an underperform rating in a research report on Sunday, November 5th. Piper Jaffray Companies restated a hold rating and set a $12.00 target price on shares of Teva Pharmaceutical Industries in a research report on Friday, November 3rd. Morgan Stanley lowered their target price on shares of Teva Pharmaceutical Industries from $14.00 to $7.00 and set an underweight rating on the stock in a research report on Friday, November 3rd. Finally, Deutsche Bank AG lowered shares of Teva Pharmaceutical Industries from a buy rating to a hold rating and set a $14.00 price objective on the stock. in a research report on Friday, November 3rd. Seven research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of Hold and an average target price of $21.88.
Teva Pharmaceutical Industries (NYSE:TEVA) traded up $0.23 during mid-day trading on Monday, reaching $13.70. 15,940,000 shares of the company’s stock were exchanged, compared to its average volume of 26,860,000. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.49. The firm has a market capitalization of $14,670.00, a PE ratio of 3.11 and a beta of 0.52.
A number of hedge funds have recently made changes to their positions in the stock. Fieldpoint Private Securities LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at about $171,000. Arthur Zaske & Associates LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at about $372,000. Sterling Capital Management LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at about $263,000. Point72 Asset Management L.P. acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at about $2,200,000. Finally, Chevy Chase Trust Holdings Inc. raised its stake in Teva Pharmaceutical Industries by 81.5% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock valued at $215,000 after purchasing an additional 5,497 shares during the last quarter. 52.29% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-pt-lowered-to-14-00-at-susquehanna-bancshares-inc/1762562.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.